Contact PI/Project LeaderACHILEFU, SAMUEL Other PIs
Awardee OrganizationUT SOUTHWESTERN MEDICAL CENTER
Description
Abstract Text
Interest in the use of optical imaging instruments in medical interventions stems from their ease of use, rapid
adaptation to clinical needs, portability, real-time feedback, and relatively low cost. Of particular interest is the
role of optical imaging in oncology. Surgery is the primary curative method for solid tumors confined to the tissue
of origin with the goal of completely removing both the tumor mass and microscopic lesions. Unfortunately, the
irregular growth pattern and infiltrations into surrounding healthy tissue prevent complete removal in many cases,
resulting in positive surgical margins (PSMs). PSMs are prevalent in oncologic surgery, increasing cancer
recurrence rates and often necessitates a second surgery to improve disease-specific survival. While PSM
occurrence is significant in advanced clinical centers, the situation is worse in many rural hospitals and resource-
limited areas due to limited histology infrastructure and workforce needed for margin assessment. Thus there is
an urgent need for an intraoperative imaging system to visualize cancer, guide tumor removal, and determine
margin positivity in the operating room (OR) in low and high resource settings alike.
Handheld fluorescence imaging systems have been developed to aid cancer resection. Still, they suffer from
several limitations, including a significant footprint in the OR and the inability of the operating surgeon to directly
control the imaging device while performing surgery. To address these shortcomings, we developed a head-
mounted display device (HMD) cancer imaging system for real-time intraoperative fluorescence-guided surgery
(FGS). The system HMD captures near-infrared (NIR) fluorescence and color images from the surgical bed and
displays accurately aligned color-NIR images in real-time, enabling FGS without disrupting surgical workflow.
The HMD has a small footprint, is intuitive to use, and is amenable for widespread use, including non-cancer
applications such as imaging of peripheral blood flow. Preliminary testing of the HMD system in human cancer
patients identified some areas for improvement that will accelerate the eventual clinical adoption of the system
worldwide. Addressing these needs requires expertise in packaging software development for medical devices
with DICOM image format and user interface development using human factors engineering. We have teamed
up with a company that has both expertise and experience in developing augmented reality/mixed reality
(AR/VR) software combined with deep machine learning in wearable devices on this project. Together, we will
optimize the system performance and ergonomics using human factors engineering. The collaborative project
will (1) develop and validate an automated fluorescence thresholding algorithm for tumor delineation; (2) develop
and validate automated registration of augmented reality in the system; and (3) develop and evaluate clinical
software to improve user experience.
At the completion of this project, we expect to develop and validate a clinic-ready, user-friendly HMD system
with a small hardware footprint, enabling seamless integration with surgical workflow to enhance clinical
adoption. The system will increase the rates and decrease the time of successful tumor resection. Anticipated
low cost and ease of use will expand adoption in low and high resource settings worldwide. This objective
approach to cancer surgery will reduce the incidence of PSMs and improve treatment outcomes.
Public Health Relevance Statement
Narrative
Optical imaging instruments have permeated medical practice because of their ease of use, rapid adaptation
to clinical needs, portability, real-time feedback, and relatively low cost. We have developed a wearable head-
mounted display device that is augmented by visible and near-infrared fluorescence imaging of tissues in real-
time. In collaboration with an industry partner, we will optimize the device performance and ergonomics using
human factors engineering. Successful completion of the research will accelerate its clinical translation and
adoption in both high- and low-resource communities.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
800771545
UEI
YZJ6DKPM4W63
Project Start Date
01-June-2022
Project End Date
31-December-2025
Budget Start Date
01-January-2024
Budget End Date
31-December-2025
Project Funding Information for 2024
Total Funding
$483,907
Direct Costs
$346,472
Indirect Costs
$137,435
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$483,907
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01EB030987-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EB030987-04
Patents
No Patents information available for 5R01EB030987-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EB030987-04
Clinical Studies
No Clinical Studies information available for 5R01EB030987-04
News and More
Related News Releases
No news release information available for 5R01EB030987-04
History
No Historical information available for 5R01EB030987-04
Similar Projects
No Similar Projects information available for 5R01EB030987-04